Aurinia Pharmaceuticals IncEducacional
Achieving Highest Complete Remission Rate of Any Lupus study
- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001)
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com/press-releases/detail/73
seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com/press-releases/detail/73
seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.